Literature DB >> 22491193

Age-dependent structural connectivity effects in fragile x premutation.

Jun Yi Wang1, David H Hessl, Randi J Hagerman, Flora Tassone, Susan M Rivera.   

Abstract

OBJECTIVE: To examine the effects of premutation alleles on major brain fiber tracts in males.
DESIGN: Cross-sectional study performed in 2007-2009.
SETTING: Institutional practice. PATIENTS: Fifteen younger (18-45 years old) carriers, 11 older (>45 years old) unaffected carriers, and 15 older carriers with fragile X-associated tremor/ataxia syndrome, together with 19 younger and 15 older controls matched by age and educational level. MAIN OUTCOME MEASURES: Diffusion tensor imaging was performed on all study participants. Eleven fiber tracts important for motor, social, emotional, and cognitive functions were reconstructed and quantified. Complementary tract-based spatial statistical analyses were performed in core white matter.
RESULTS: In the younger carriers, premutation status was associated with a greater age-related connectivity decline in the extreme capsule. Among older carriers, unaffected individuals did not display structural alterations, whereas the affected carriers showed connectivity loss in 5 fiber tracts and exhibited greater age-related connectivity decline in all 11 tracts compared with the controls. In addition, 9 fiber tracts showed significantly higher variability relative to the controls, and symptom severity explained the variability in 6 measurements from the superior cerebellar peduncle, corpus callosum, and cingulum.
CONCLUSIONS: The findings revealed widespread alterations in structural connectivity associated with fragile X-associated tremor/ataxia syndrome and preserved or subtle changes in structural connectivity in unaffected carriers. Diffusion tensor imaging is sensitive to pathologic changes in the white matter associated with this neurodegenerative disorder. Wang et al examine the effects of premutation alleles on major brain fiber tracts in males, who are at risk of developing fragile X-associated tremor/ataxia syndrome and may manifest subtle cognitive, social, and emotional disturbances before clinical involvement.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22491193      PMCID: PMC3979438          DOI: 10.1001/archneurol.2011.2023

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  35 in total

1.  Molecular and imaging correlates of the fragile X-associated tremor/ataxia syndrome.

Authors:  S Cohen; K Masyn; J Adams; D Hessl; S Rivera; F Tassone; J Brunberg; C DeCarli; L Zhang; J Cogswell; D Loesch; M Leehey; J Grigsby; P J Hagerman; R Hagerman
Journal:  Neurology       Date:  2006-10-24       Impact factor: 9.910

2.  Symmetries in human brain language pathways correlate with verbal recall.

Authors:  Marco Catani; Matthew P G Allin; Masud Husain; Luca Pugliese; Marsel M Mesulam; Robin M Murray; Derek K Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-15       Impact factor: 11.205

3.  Reproducibility of quantitative tractography methods applied to cerebral white matter.

Authors:  Setsu Wakana; Arvind Caprihan; Martina M Panzenboeck; James H Fallon; Michele Perry; Randy L Gollub; Kegang Hua; Jiangyang Zhang; Hangyi Jiang; Prachi Dubey; Ari Blitz; Peter van Zijl; Susumu Mori
Journal:  Neuroimage       Date:  2007-03-20       Impact factor: 6.556

4.  A voxel-based morphometry study of grey matter loss in fragile X-associated tremor/ataxia syndrome.

Authors:  Ryu-ichiro Hashimoto; Alireza K Javan; Flora Tassone; Randi J Hagerman; Susan M Rivera
Journal:  Brain       Date:  2011-03       Impact factor: 13.501

5.  A rapid polymerase chain reaction-based screening method for identification of all expanded alleles of the fragile X (FMR1) gene in newborn and high-risk populations.

Authors:  Flora Tassone; Ruiqin Pan; Khaled Amiri; Annette K Taylor; Paul J Hagerman
Journal:  J Mol Diagn       Date:  2007-12-28       Impact factor: 5.568

Review 6.  How do you feel--now? The anterior insula and human awareness.

Authors:  A D Bud Craig
Journal:  Nat Rev Neurosci       Date:  2009-01       Impact factor: 34.870

7.  Cognitive profile of fragile X premutation carriers with and without fragile X-associated tremor/ataxia syndrome.

Authors:  Jim Grigsby; Angela G Brega; Karen Engle; Maureen A Leehey; Randi J Hagerman; Flora Tassone; David Hessl; Paul J Hagerman; Jennifer B Cogswell; Rachael E Bennett; Kylee Cook; Deborah A Hall; Lanee S Bounds; Marsha J Paulich; Ann Reynolds
Journal:  Neuropsychology       Date:  2008-01       Impact factor: 3.295

8.  Lifespan changes in working memory in fragile X premutation males.

Authors:  Kim M Cornish; Cary S Kogan; Lexin Li; Jeremy Turk; Sebastien Jacquemont; Randi J Hagerman
Journal:  Brain Cogn       Date:  2008-12-27       Impact factor: 2.310

9.  Mood and anxiety disorders in females with the FMR1 premutation.

Authors:  Jane E Roberts; Donald B Bailey; Jean Mankowski; Amy Ford; John Sideris; Leigh Anne Weisenfeld; T Morgan Heath; Robert N Golden
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2009-01-05       Impact factor: 3.568

10.  Tract-based spatial statistics: voxelwise analysis of multi-subject diffusion data.

Authors:  Stephen M Smith; Mark Jenkinson; Heidi Johansen-Berg; Daniel Rueckert; Thomas E Nichols; Clare E Mackay; Kate E Watkins; Olga Ciccarelli; M Zaheer Cader; Paul M Matthews; Timothy E J Behrens
Journal:  Neuroimage       Date:  2006-04-19       Impact factor: 6.556

View more
  33 in total

Review 1.  Fragile X-associated tremor/ataxia syndrome (FXTAS): pathology and mechanisms.

Authors:  Paul Hagerman
Journal:  Acta Neuropathol       Date:  2013-06-21       Impact factor: 17.088

2.  Open-Label Allopregnanolone Treatment of Men with Fragile X-Associated Tremor/Ataxia Syndrome.

Authors:  J Y Wang; A M Trivedi; N R Carrillo; J Yang; A Schneider; C Giulivi; P Adams; F Tassone; K Kim; S M Rivera; N Lubarr; C-Y Wu; R W Irwin; R D Brinton; J M Olichney; M A Rogawski; R J Hagerman
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

Review 3.  The fragile X mental retardation 1 gene (FMR1): historical perspective, phenotypes, mechanism, pathology, and epidemiology.

Authors:  Jim Grigsby
Journal:  Clin Neuropsychol       Date:  2016-06-29       Impact factor: 3.535

4.  Risk Factors for Cognitive Impairment in Fragile X-Associated Tremor/Ataxia Syndrome.

Authors:  Andreea L Seritan; Kyoungmi Kim; Ian Benjamin; Ioana Seritan; Randi J Hagerman
Journal:  J Geriatr Psychiatry Neurol       Date:  2016-09-21       Impact factor: 2.680

Review 5.  Fragile X-associated tremor/ataxia syndrome.

Authors:  Paul J Hagerman; Randi J Hagerman
Journal:  Ann N Y Acad Sci       Date:  2015-01-26       Impact factor: 5.691

6.  Can a Neurosteroid Ameliorate Fragile X-Associated Tremor/Ataxia Syndrome?

Authors:  Dejan B Budimirovic
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

7.  Eye movements reveal impaired inhibitory control in adult male fragile X premutation carriers asymptomatic for FXTAS.

Authors:  Ling M Wong; Naomi J Goodrich-Hunsaker; Yingratana McLennan; Flora Tassone; Melody Zhang; Susan M Rivera; Tony J Simon
Journal:  Neuropsychology       Date:  2014-04-28       Impact factor: 3.295

8.  Influence of the fragile X mental retardation (FMR1) gene on the brain and working memory in men with normal FMR1 alleles.

Authors:  Jun Yi Wang; David Hessl; Christine Iwahashi; Katherine Cheung; Andrea Schneider; Randi J Hagerman; Paul J Hagerman; Susan M Rivera
Journal:  Neuroimage       Date:  2012-10-12       Impact factor: 6.556

9.  Language dysfluencies in females with the FMR1 premutation.

Authors:  Audra M Sterling; Marsha Mailick; Jan Greenberg; Steven F Warren; Nancy Brady
Journal:  Brain Cogn       Date:  2013-03-20       Impact factor: 2.310

10.  Altered structural brain connectome in young adult fragile X premutation carriers.

Authors:  Alex Leow; Danielle Harvey; Naomi J Goodrich-Hunsaker; Johnson Gadelkarim; Anand Kumar; Liang Zhan; Susan M Rivera; Tony J Simon
Journal:  Hum Brain Mapp       Date:  2014-02-27       Impact factor: 5.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.